When was keytruda approved by the fda for use in cancer therapy?

Keytruda's FDA Approval Timeline

Keytruda, the brand name for pembrolizumab, is a checkpoint inhibitor used in cancer therapy. [1] [2]

The FDA granted Keytruda accelerated approval for use in the treatment of patients with metastatic melanoma in September 2014. [3] This was followed by its approval in June 2017 for use in combination with other medications for patients with a type of lymphoma called classical Hodgkin lymphoma. [4]

Approval Milestones

- September 2014: Keytruda was granted accelerated approval by the FDA for the treatment of patients with metastatic melanoma, whose cancer had progressed on two or more previous therapies. [5]
- June 2017: The FDA approved Keytruda for use in combination with other medications for patients with classical Hodgkin lymphoma.

Expanding to New Indications

Keytruda continues to be studied and approved for various uses, including in combination with chemotherapy for patients with head and neck cancer, certain types of lung cancer, and renal cell carcinoma, among others. [6]